HEATHER HAS TWO MOMMIES, SCIENCE-STYLE
FDA advisory committee grapples with egg cell modification’s scientific side
By Anette Breindl
Thursday, February 27, 2014
As an FDA advisory committee met over the past two days to discuss what it would take for clinical trials of “oocyte modification in assisted reproduction for the prevention of transmission of mitochondrial disease or treatment of infertility” to go forward, the committee was trying walk the line between sticking to their part of the issue – the science that would inform such trials – and acknowledging that the science was not the only, and not even the most important, issue about whether such trials would be a good idea.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.